Supernus Pharmaceuticals Cash Flow Statement
NASDAQ: SUPNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Supernus Pharmaceuticals free cash flow
In fiscal 2025, Supernus Pharmaceuticals generated $47.3 million of operating cash flow and spent $1.3 million on capital expenditures. That left free cash flow of $46.0 million, a free-cash-flow margin of 6.4% of revenue. Free cash flow was down 73.1% from the prior year's $171.2 million.
Summary generated from market data by MetaCap's automated system. Methodology
Supernus Pharmaceuticals cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -38.55M | 73.86M | 1.32M | 60.71M | 53.42M | 126.95M | 113.06M | 110.99M | 57.28M | 91.22M |
| Net Income growth (YoY) | -152.19% | +5512.84% | -97.83% | +13.64% | -57.92% | +12.29% | +1.86% | +93.76% | -37.20% | +554.20% |
| Depreciation & Amortization | 91.56M | 80.41M | 84.86M | 85.54M | 32.59M | 18.14M | 6.66M | 7.06M | 8.13M | 2.40M |
| Stock-Based Compensation | 33.05M | 27.75M | 26.76M | 17.57M | 17.91M | 16.56M | 14.85M | 11.29M | 8.43M | 5.93M |
| Change in Working Capital | -67.55M | -16.48M | -11.75M | -41.08M | 7.47M | -36.46M | 21.74M | -38.36M | -21.29M | -6.52M |
| Operating Cash Flow | 47.33M | 171.95M | 111.08M | 116.83M | 127.13M | 138.40M | 143.13M | 128.99M | 114.64M | 66.81M |
| Capital Expenditures | -1.34M | -725.00K | -551.00K | -412.00K | — | -3.45M | -2.74M | -844.00K | -2.03M | -1.60M |
| Investing Cash Flow | 4.11M | -189.87M | 268.73M | -216.66M | -81.91M | -34.70M | -157.92M | -413.48M | -86.42M | -35.96M |
| Financing Cash Flow | 9.13M | 12.19M | -397.88M | -10.48M | -130.42M | 3.56M | 3.93M | 376.44M | 5.68M | 2.05M |
| Net Change in Cash | 60.57M | -5.72M | -18.07M | -110.31M | -85.21M | 107.26M | -10.87M | 91.94M | 33.91M | 32.90M |
| Free Cash Flow | 45.99M | 171.23M | 110.53M | 116.41M | 127.13M | 134.95M | 140.39M | 128.14M | 112.61M | 65.21M |
This table shows 10 annual periods of Supernus Pharmaceuticals's cash flow statement, from FY 2025 back to FY 2016, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow SUPN's reporting calendar. What is a cash flow statement?